CA3021752A1 - Formulations nanoparticulaires d'ivacaftor - Google Patents

Formulations nanoparticulaires d'ivacaftor Download PDF

Info

Publication number
CA3021752A1
CA3021752A1 CA3021752A CA3021752A CA3021752A1 CA 3021752 A1 CA3021752 A1 CA 3021752A1 CA 3021752 A CA3021752 A CA 3021752A CA 3021752 A CA3021752 A CA 3021752A CA 3021752 A1 CA3021752 A1 CA 3021752A1
Authority
CA
Canada
Prior art keywords
ivacaftor
nanoparticulate
composition
less
pharmaceutically acceptable
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA3021752A
Other languages
English (en)
Inventor
Sai Sumana PENUMETCHA
Srikanta PATRA
Bhavani Prasanna Kumar BIMIREDDY
Harish DHANALA
Varma S. Rudraraju
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
AIZANT DRUG RESEARCH SOLUTIONS PRIVATE Ltd
Original Assignee
AIZANT DRUG RESEARCH SOLUTIONS PRIVATE Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by AIZANT DRUG RESEARCH SOLUTIONS PRIVATE Ltd filed Critical AIZANT DRUG RESEARCH SOLUTIONS PRIVATE Ltd
Publication of CA3021752A1 publication Critical patent/CA3021752A1/fr
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/145—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/167—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction with an outer layer or coating comprising drug; with chemically bound drugs or non-active substances on their surface
    • A61K9/1676—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction with an outer layer or coating comprising drug; with chemically bound drugs or non-active substances on their surface having a drug-free core with discrete complete coating layer containing drug
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat

Abstract

La présente invention concerne des compositions nanoparticulaires d'ivacaftor ou leur sel pharmaceutiquement acceptable, et des procédés de fabrication et d'utilisation de ces compositions. Les compositions comprennent des particules d'ivacaftor possédant une taille de particule moyenne efficace inférieure à environ 2 000 nm. L'invention comprend également au moins un stabilisant de surface et éventuellement un ou plusieurs excipients pharmaceutiquement acceptables.
CA3021752A 2015-06-11 2016-06-10 Formulations nanoparticulaires d'ivacaftor Abandoned CA3021752A1 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
IN2936/CHE/2015 2015-06-11
IN2936CH2015 2015-06-11
PCT/IB2016/053433 WO2016199085A1 (fr) 2015-06-11 2016-06-10 Formulations nanoparticulaires d'ivacaftor

Publications (1)

Publication Number Publication Date
CA3021752A1 true CA3021752A1 (fr) 2016-12-15

Family

ID=57503253

Family Applications (1)

Application Number Title Priority Date Filing Date
CA3021752A Abandoned CA3021752A1 (fr) 2015-06-11 2016-06-10 Formulations nanoparticulaires d'ivacaftor

Country Status (2)

Country Link
CA (1) CA3021752A1 (fr)
WO (1) WO2016199085A1 (fr)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN113925863A (zh) * 2020-06-29 2022-01-14 四川大学华西医院 Ivacaftor在制备抑制新型冠状病毒SARS-CoV2的药物中的用途
EP4335434A1 (fr) * 2022-08-17 2024-03-13 Sanovel Ilac Sanayi Ve Ticaret A.S. Compositions pharmaceutiques comprenant l'ivacaftor

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20100074949A1 (en) 2008-08-13 2010-03-25 William Rowe Pharmaceutical composition and administration thereof
LT2489659T (lt) 2004-06-24 2018-03-26 Vertex Pharmaceuticals Incorporated Atp rišančios kasetės transporterių moduliatoriai
RS60205B1 (sr) 2005-12-28 2020-06-30 Vertex Pharma Farmaceutske kompozicije amorfnog oblika n-[2,4-bis(1,1-dimetiletil)-5-hidroksifenil]-1,4-dihidro-4-oksohinolin-3-karboksamida
LT2821400T (lt) 2009-03-20 2018-02-12 Vertex Pharmaceuticals Incorporated Cistinės fibrozės transmembraninio laidumo reguliatoriaus moduliatorių gamybos būdas
CN109966264A (zh) 2012-02-27 2019-07-05 沃泰克斯药物股份有限公司 药物组合物及其施用
HUP1600270A2 (hu) * 2016-04-25 2017-10-30 Druggability Tech Ip Holdco Ltd Ivacaftornak, sóinak és származékainak komplexei, eljárás azok elõállítására és azok gyógyszerészetileg elfogadott készítményei
US11384054B2 (en) * 2020-10-22 2022-07-12 Scinopharm Taiwan, Ltd. Crystalline form of ivacaftor and a process for preparing the same
EP4299053A1 (fr) * 2022-06-28 2024-01-03 Vysoká skola chemicko-technologická v Praze Procédé de préparation d'un nanosuspension aqueuse contenant des nanocristaux d'ingrédient pharmaceutiquement actif et une combinaison de stabilisateurs, nanosuspension aqueuse, et utilisation associée

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN109966264A (zh) * 2012-02-27 2019-07-05 沃泰克斯药物股份有限公司 药物组合物及其施用
US8674108B2 (en) * 2012-04-20 2014-03-18 Vertex Pharmaceuticals Incorporated Solid forms of N-[2,4-bis(1,1-dimethylethy)-5-hydroxyphenyl]-1,4-dihydro-4-oxoquinoline-3-carboxamide

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN113925863A (zh) * 2020-06-29 2022-01-14 四川大学华西医院 Ivacaftor在制备抑制新型冠状病毒SARS-CoV2的药物中的用途
CN113925863B (zh) * 2020-06-29 2023-01-31 四川大学华西医院 Ivacaftor在制备抑制新型冠状病毒SARS-CoV2的药物中的用途
EP4335434A1 (fr) * 2022-08-17 2024-03-13 Sanovel Ilac Sanayi Ve Ticaret A.S. Compositions pharmaceutiques comprenant l'ivacaftor

Also Published As

Publication number Publication date
WO2016199085A1 (fr) 2016-12-15

Similar Documents

Publication Publication Date Title
CA3021752A1 (fr) Formulations nanoparticulaires d'ivacaftor
US9012511B2 (en) Nanoparticulate cinacalcet compositions
AU2006309295B2 (en) Nanoparticulate acetaminophen formulations
US20070148100A1 (en) Nanoparticulate aripiprazole formulations
US20070281011A1 (en) Nanoparticulate posaconazole formulations
US20080213374A1 (en) Nanoparticulate sorafenib formulations
JP2009518300A (ja) モメタゾン組成物ならびにその作製方法および使用方法
KR20080016952A (ko) 나노입자형 클로피도그렐과 아스피린의 배합 제제
US20090291142A1 (en) Nanoparticulate bicalutamide formulations
JP2023062070A (ja) インジルビンのナノ微粒子、その誘導体およびそれらを作製しかつ利用する方法
EP1898882B1 (fr) Formulations d'ebastine nanoparticulaire
US20090297596A1 (en) Nanoparticulate and Controlled Release Compositions Comprising a Platelet Aggregation Inhibitor
US20100221327A1 (en) Nanoparticulate azelnidipine formulations
CA2654909A1 (fr) Formulations d'inhibiteurs de kinase nanoparticulaires
MX2007015304A (en) Nanoparticulate acetaminophen formulations

Legal Events

Date Code Title Description
FZDE Discontinued

Effective date: 20220902

FZDE Discontinued

Effective date: 20220902